Navigation Links
Pharma Companies May Influence The Decisions Of Medical Students

According to a report in the latest issue of JAMA, which deals with medical education as a theme, the third year medical students of US medical schools receive on an average one gift or attend one //event sponsored by a drug company per week and often feel that sponsored educational events are biased.

Medical students are entering an environment with progressively fewer boundaries between medicine and the pharmaceutical industry, which spends $12 billion to $18 billion annually marketing to physicians (including residents), according to background information in the article.

This includes 60 million visits annually by pharmaceutical representatives and most of the $1.54 billion spent annually on continuing medical education. Drug company–physician interaction presents information favoring the sponsor’s product and increases the likelihood of prescribing that product. Prescribing may be inconsistent with evidence-based guidelines and may reflect the presence of drug samples or patient demand due to direct-to-consumer advertising, even if a drug was not the physician’s first choice. While exposure to and attitudes about drug company interactions among residents have been studied extensively, relatively little is known about relationships between drug companies and medical students.

Researchers from Rosalind Franklin University of Medicine and Science had measured the frequency of medical students’ exposure to drug company gifts, students’ attitudes about gifts, and correlates of these frequencies and attitudes. In 2003 the researchers distributed a 64-item anonymous survey to 1,143 third-year students at 8 U.S. medical schools, exploring their exposure and response to drug company interactions. In 2005, the researchers conducted a national survey of student affairs deans to measure the prevalence of school-wide policies on drug company–medical student interactions.

The overall response rate of the surveys was 72.3 percent (
'"/>




Page: 1 2

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharma cos must forge Strategic alliances
4. Medicis Pharmaceutical company enters pediatric market
5. Pharma majors gear to supply anti-anthrax drug
6. Pharmacies in for a dose of bitter medicine
7. Andhra Pradesh to set up Pharma City
8. Sun Pharma to launch chiral version of omeprazole soon
9. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
10. Pharmacia may take 51.5 percent Abbott stake
11. Pharmaceutical companies are targeting patients
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...Marriage guidance counseling sessions are sometime... blame and slow to accept responsibility for a rel...ouples report progress, the others say counseling ...hed positions. An Australian psychologist is expe...
...PASADENA, Calif., June 6 /PRNewswire-USNewswire/ -...e and monitor treatments for hardening of the arte...attacks and strokes. Hospitals and doctors around... software initially developed at NASA's Jet Propul...
...A solar torch, homemade compost machine, jute bags...made from poly packs, salt-rock lamps and many mo...el here to spread awareness about a cleaner future...i to think in terms of environment and make Delhi ...
...RARITAN, N.J., Johnson & Johnson Pharmaceutical Re...hat it has submitted a New Drug Application (NDA) ...(FDA) for doripenem, an investigational carbapene...socomial pneumonia, a pneumonia that is acquired i...
Other Medicine News:Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 2Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 3Health News:A Welcome Initiative to Spread Awareness on Environment 2
(Date:9/3/2008)...ease Awareness Month, CHARLOTTESVILLE, Va., Sept....a clinical-stage drug-development company commerci...al needs, announced today that it has begun,to enr... lead drug,candidate trans sodium crocetinate (TSC...altrials.gov Website, is investigating TSC as a tr...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...lans with FDA, PRINCETON, N.J., Sept. 3 /PRNewswi...hat it successfully completed two key clinical tri...ative low-dose, once-weekly,contraceptive patch, ...t,code AG-200-15. The Phase 2b safety and efficacy...ulation suppression, cycle control and safety. The...
(Date:9/3/2008)...nce Pycnogenol(R) Lowers Joint, Pain, Symptoms; Ma...ation of the Extract, ...to the Center for,Disease Control (CDC), osteoarth...e rise. A new study published in the August journa... bark extract from the French maritime pine,tree, ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 1Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 2Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 3Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 4Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 5New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 1New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 2
... WIRE)--May 1, 2007 - Teva,Pharmaceutical Industri... data from a 36-week, randomized, double-blind,pl... an oral 0.6 mg,dose of laquinimod given daily sig...) disease activity by 38 percent in RRMS,patients ...avorable,trend towards reducing annual relapse rat...
...isease Activity as Measured,by MRI and Relapse --...nc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BII...inical study of Rituxan®,(rituximab) in patien...MS) were presented today at the American Academy o... is a therapeutic antibody,that targets and select...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ic stools come with five legs for extra stability....ical travel 6"). 2" ball bearing swivel hard rubbe... upholstery, available in black vinyl as standard,... a contoured, padded, upholstered backrest, with v...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Medicine Products: